Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 201592, 11 pages
http://dx.doi.org/10.1155/2015/201592
Research Article

Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

1Department of Psychiatry, Shimane University School of Medicine, Izumo, Japan
2Research Institute of Traditional Asian Medicine, Kinki University, Higashi-Osaka, Japan
3Center for Advance Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan
4Psychiatry & Neurology, Hamamatsu University School of Medicine, Hamamatsu, Japan
5Psychiatry, Kanazawa University School of Medicine, Kanazawa, Japan
6Psychiatry, Chiba University School of Medicine, Chiba, Japan
7Psychiatry, Ehime University School of Medicine, Matsuyama, Japan
8Medical Center for Translational Research, Osaka University Hospital, Suita, Japan
9Psychiatry, Takeda General Hospital, Fukushima, Japan
10Psychiatry, Matsue Aoba Hospital, Matsue, Japan

Received 18 November 2014; Accepted 16 March 2015

Academic Editor: Yuping Tang

Copyright © 2015 Tsuyoshi Miyaoka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. R. Conley and R. W. Buchanan, “Evaluation of treatment-resistant schizophrenia,” Schizophrenia Bulletin, vol. 23, no. 4, pp. 663–674, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Aizawa, T. Kanbayashi, Y. Saito et al., “Effects of yoku-kan-san-ka-chimpi-hange on the sleep of normal healthy adult subjects,” Psychiatry and Clinical Neurosciences, vol. 56, no. 3, pp. 303–304, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Tahara, T. Shimizu, and K. Moriyama, “Two cases with positive symptoms by dementia of elderly successfully treated with yokukan-san,” Kampo no Rinsho, vol. 1, pp. 105–114, 2003 (Japanese). View at Google Scholar
  4. K. Iwasaki, M. Maruyama, N. Tomita et al., “Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies,” Journal of Clinical Psychiatry, vol. 66, no. 12, pp. 1612–1613, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Iwasaki, T. Satoh-Nakagawa, M. Maruyama et al., “A randomized observer-blind, controlled trial of the traditional Chinese medicine yi-gan san for improvement of behavioral and psychological symptoms and activities of daily living dementia patients,” Journal of Clinical Psychiatry, vol. 66, no. 2, pp. 248–252, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Miyaoka, M. Furuya, H. Yasuda, M. Hayashia, T. Inagaki, and J. Horiguchi, “Yi-gan san for the treatment of borderline personality disorder: an open-label study,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 1, pp. 150–154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Miyaoka, M. Furuya, H. Yasuda et al., “Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 3, pp. 761–764, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Miyaoka, M. Furuya, H. Yasuda et al., “Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study,” Clinical Neuropharmacology, vol. 32, no. 1, pp. 6–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Miyaoka, M. Nagahama, K. Tsuchie et al., “Charles Bonnet syndrome: successful treatment of visual hallucinations due to vision loss with Yi-gan san,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 33, no. 2, pp. 382–383, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Miyaoka and J. Horiguchi, “Clinical potential of Yi-gan san (yokukansan) for the treatment of psychiatric disorders,” Current Psychiatry Reviews, vol. 5, no. 4, pp. 271–275, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Miyaoka, M. Furuya, L. Kristian et al., “Yi-gan san for treatment of Charles Bonnet syndrome (visual hallucination due to vision loss): an open-label study,” Clinical Neuropharmacology, vol. 34, no. 1, pp. 24–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Miyaoka, R. Wake, M. Furuya et al., “Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study,” BMC Psychiatry, vol. 12, article 215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Miyaoka, R. Wake, M. Furuya et al., “Yokukansan (TJ-54) for treatment of very-late-onset schizophrenia-like psychosis: an open-label study,” Phytomedicine, vol. 20, no. 7, pp. 654–658, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Wake, T. Miyaoka, T. Inagaki et al., “Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study,” Journal of Child and Adolescent Psychopharmacology, vol. 23, no. 5, pp. 329–336, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Mizukami, T. Asada, T. Kinoshita et al., “A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia,” International Journal of Neuropsychopharmacology, vol. 12, no. 2, pp. 191–199, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Monji, M. Takita, T. Samejima et al., “Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease,” Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 33, no. 2, pp. 308–311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Kawanabe, A. Yoritaka, H. Shimura, H. Oizumi, S. Tanaka, and N. Hattori, “Successful treatment with Yokukansan for behavioral and psychological symptoms of Parkinsonian dementia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 2, pp. 284–287, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Okahara, Y. Ishida, Y. Hayashi et al., “Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease,” Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 34, no. 3, pp. 532–536, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Hayashi, Y. Ishida, T. Inoue et al., “Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 3, pp. 541–545, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Kimura, H. Hayashida, H. Furukawa, and J. Takamatsu, “Pilot study of pharmacological treatment for frontotemporal dementia: effect of Yokukansan on behavioral symptoms,” Psychiatry and Clinical Neurosciences, vol. 64, no. 2, pp. 207–210, 2010. View at Publisher · View at Google Scholar
  21. K. Iwasaki, K. Kosaka, H. Mori et al., “Open label trial to evaluate the efficacy and safety of yokukansan, a traditional Asian medicine, in dementia with Lewy bodies,” Journal of the American Geriatrics Society, vol. 59, no. 5, pp. 936–938, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Sumiyoshi, A. Mantani, S. Nishiyama et al., “Yokukansan treatment in chronic renal failure patients with dementia receiving hemodialysis: an open label study,” The American Journal of Geriatric Psychiatry, vol. 19, no. 10, pp. 906–907, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Nagata, E. Yokoyama, T. Yamazaki et al., “Effects of yokukansan on behavioral and psychological symptoms of vascular dementia: an open-label trial,” Phytomedicine, vol. 19, no. 6, pp. 524–528, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Kajitani and S. Kanba, “Successful treatment of poststroke emotional incontinence with Yokukansan, an Asian herbal medicine: report of two cases,” Journal of the American Geriatrics Society, vol. 60, no. 2, pp. 379–381, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Iwasaki, K. Kosaka, H. Mori et al., “Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine,” Psychogeriatrics, vol. 12, no. 4, pp. 235–241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. R. G. Stern, J. Schmeidler, and M. Davidson, “Limitations of controlled augmentation trials in schizophrenia,” Biological Psychiatry, vol. 42, no. 2, pp. 138–143, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Text Revision, American Psychiatric Association, Washington, DC, USA, 4th edition, 2000.
  28. M. B. First, R. l. Spitzer, M. Gibbon, and J. B. W. Williams, Structured Clinical Interview for DSM-IV Axis I Disorders, American Psychiatric Press, New York, NY, USA, 1995.
  29. S. R. Kay, A. Fiszbein, and L. A. Opler, “The positive and negative syndrome scale (PANSS) for schizophrenia,” Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Guy, ECDEU Assessment Manual for Psychopharmacogy—Revised, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, Rockville, Md, USA, 1976.
  31. J. M. Kane, G. Honigfeld, J. Singer, and H. Meltzer, “Clozapine in treatment-resistant schizophrenics,” Psychopharmacology Bulletin, vol. 24, no. 1, pp. 62–67, 1988. View at Google Scholar · View at Scopus
  32. T. Inada, G. Yagi, and G. Gardos, “Inter-rater reliability of the drug-induced extrapyramidal symptoms scale (DIEPSS),” in PRoceedings of the 20th Collegium International Neuropsychopharmacologium, pp. 23–27, Melborune, Australia, 2009.
  33. R. D. Gibbons, D. Hedeker, I. Elkin et al., “Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of depression collaborative research program dataset,” Archives of General Psychiatry, vol. 50, no. 9, pp. 739–750, 1993. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Egashira, K. Iwasaki, A. Ishibashi et al., “Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 6, pp. 1516–1520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Terawaki, Y. Ikarashi, K. Sekiguchi, Y. Nakai, and Y. Kase, “Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells,” Journal of Ethnopharmacology, vol. 127, no. 2, pp. 306–312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Kawakami, H. Kanno, T. Ueki et al., “Neuroprotective effects of yokukansan, a traditional Japanese medicine, on glutamate-mediated excitotoxicity in cultured cells,” Neuroscience, vol. 159, no. 4, pp. 1397–1407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Ikarashi, S. Iizuka, S. Imamura et al., “Effects of yokukansan, a traditional Japanese medicine, on memory disturbance and behavioral and psychological symptoms of dementia in thiamine-deficient rats,” Biological and Pharmaceutical Bulletin, vol. 32, no. 10, pp. 1701–1709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Shimada, H. Goto, T. Kogure et al., “Protective effect of phenolic compounds isolated from the hooks and stems of Uncaria sinensis on glutamate-induced neuronal death,” The American Journal of Chinese Medicine, vol. 29, no. 1, pp. 173–180, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Shimada, H. Goto, T. Itoh et al., “Evaluation of the protective effects of alkaloids isolated from the hooks and stems of Uncaria sinensis on glutamate-induced neuronal death in cultured cerebellar granule cells from rats,” Journal of Pharmacy and Pharmacology, vol. 51, no. 6, pp. 715–722, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. T. H. Kang, Y. Murakami, K. Mastumoto et al., “Rhyncoohyline and isorhynchophyline inhibit NMDA receptors expressed in Xenopus oocytes,” European Journal of Pharmacology, vol. 455, pp. 27–34, 2002. View at Google Scholar
  41. H. Kanatani, H. Kohda, K. Yamasaki et al., “The active principles of the branchlet and hood of Uncaria sinensis Oliv. examined with a 5-hydroxytryptamine receptor binding assay,” Journal of Pharmacy and Pharmacology, vol. 37, no. 6, pp. 401–404, 1985. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Nishi, T. Yamaguchi, K. Sekiguchi, Y. Ikarashi, and Y. Kase, “Ameliorative effect of yokukansan an aggressive behavior in social isolated mice,” in Proceedings of the 40th Annual Meeting of Japanese Society of Neuropsychopharmacology, Abstract P176, Sendai, Japan, September 2010.
  43. H. Kanno, K. Sekiguchi, T. Yamaguchi et al., “Effect of yokukansan, a traditional Japanese medicine, on social and aggressive behaviour of para-chloroamphetamine-injected rats,” Journal of Pharmacy and Pharmacology, vol. 61, no. 9, pp. 1249–1256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Kapur, R. B. Zipursky, and G. Remington, “Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia,” The American Journal of Psychiatry, vol. 156, no. 2, pp. 286–293, 1999. View at Google Scholar · View at Scopus